Wanbang Pharmaceutical Holding Group's subsidiary Shishanjianjia controlled-release tablets obtained ethical approval.

Wanbangde Pharmaceutical Holding Group (002082.SZ) announced that its wholly-owned subsidiary, Wanbangde Pharmaceutical Holding Group Pharmaceutical Group Co., Ltd., has received approval from the Ethics Committee of the Capital Medical University Xuanwu Hospital for the key registration clinical trial of the 2.2 class new drug Shishanjian Jia controlled-release tablets for the treatment of mild to moderate Alzheimer's disease dementia. Shishanjian Jia controlled-release tablets is a 2.2 class new drug independently developed by the company for the treatment of mild to moderate Alzheimer's disease dementia. It adopts dual-phase controlled-release technology, with a smooth drug release peak-valley curve and prolonged drug release time in the body, achieving rapid onset, reduced adverse reactions, increased drug dosage, and good safety. At the same time, the controlled-release technology allows for once-daily dosing, reducing the frequency and improving patient compliance.